Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

4/15/24 6:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AUPH alert in real time by email

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company's head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415733514/en/

Get the next $AUPH alert in real time by email

Date	Price Target	Rating	Analyst
11/4/2022		Outperform → Perform	Oppenheimer
5/5/2022	$34.00 → $25.00	Overweight	Cantor Fitzgerald
3/8/2022	$30.00 → $22.00	Outperform	SVB Leerink
3/1/2022	$31.00 → $27.00	Outperform	RBC Capital
2/23/2022	$34.00 → $31.00	Outperform	RBC Capital
12/10/2021	$33.00 → $31.00	Perform → Outperform	Oppenheimer
11/4/2021	$32.00 → $33.00	Perform	Oppenheimer
11/4/2021	$35.00 → $40.00	Buy	HC Wainwright & Co.

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

Chat with this insight

Recent Analyst Ratings for $AUPH

$AUPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Aurinia Pharma downgraded by Oppenheimer

Cantor Fitzgerald resumed coverage on Aurinia Pharma with a new price target

SVB Leerink reiterated coverage on Aurinia Pharmaceuticals with a new price target

$AUPH Financials

Live finance-specific insights

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

$AUPH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

SEC Form SC 13D filed by Aurinia Pharmaceuticals Inc

SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

$AUPH Press Releases

Fastest customizable press release news feed in the world

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia to Participate in Jefferies London Healthcare Conference

$AUPH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for LUPKYNIS

$AUPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Bailey Jeffrey Allen converted options into 17,913 shares and sold $38,416 worth of shares (4,557 units at $8.43) (SEC Form 4)

Director Smith Karen L. converted options into 17,913 shares and sold $44,182 worth of shares (5,241 units at $8.43) (SEC Form 4)

New insider Keenan Greg claimed ownership of 111,445 shares (SEC Form 3)

$AUPH SEC Filings

$AUPH Leadership Updates

Live Leadership Updates

$AUPH Market Insights

Live Market Insights

SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia Announces 2024 Annual General Meeting Results

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

ILJIN SNT Co., Ltd Announces Intention To Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal

Aurinia Pharmaceuticals Announced An Oral Presentation At The European Alliance Of Associations For Rheumatology 2024 In Vienna, Austria June 12-15, Which Includes Safety And Efficacy Profile Of Lupkynis For People With Lupus Nephritis

Aurinia Issues Letter To Shareholders In Response To Letter From Shareholder Lucien Selce; Company Raises Concerns Surrounding Lucien Selce's Lack Of Credibility

Recent Analyst Ratings for
$AUPH

$AUPH
Analyst Ratings

$AUPH
Financials

$AUPH
Large Ownership Changes

$AUPH
Press Releases

$AUPH
FDA approvals

$AUPH
Insider Trading

$AUPH
SEC Filings

$AUPH
Leadership Updates

$AUPH
Market Insights